Molecular characteristics of mismatch repair genes in sporadic colorectal tumors in Czech patients

BMC Medical Genetics

Pavel Vodicka⁵  Alessio Naccarati³  Barbara Pardini³  Lucie Schwarzova⁵  Alexandra Rejhova⁴  Pavel Prochazka⁵  Lucie Langerova²  Ludovit Bielik¹  Vlasta Korenkova²  Jana Slyskova⁵  Veronika Polakova Vymetalkova⁵ 

[1] Faculty of Science, Charles University, Albertov 6, Prague, Czech Republic;Institute of Biotechnology, Academy of Sciences of the Czech Republic, Prague, Czech Republic;Human Genetics Foundation, Turin, Italy;Institute of Experimental Medicine Academy of Sciences of the Czech Republic, Prague, Czech Republic;Institute of Biology and Medical Genetics, First Faculty of Medicine Charles University, Prague, Czech Republic

关键词: Promoter methylation;    Expression levels;    Mismatch repair genes;    Colorectal cancer;   

Others  :  1122516
DOI  :  10.1186/1471-2350-15-17

 received in 2013-07-30, accepted in 2014-01-28,  发布年份 2014

【 摘 要 】

Background

Mismatch repair (MMR) genes are known to be frequently altered in colorectal cancer (CRC). Both genetics and epigenetics modifications seems to be relevant in this phenomenon, however it is still not clear how these two aspects are interconnected. The present study aimed at characterizing of epigenetic and gene expression profiles of MMR genes in sporadic CRC patients from the Czech Republic, a country with one of the highest incidences of this cancer all over Europe.

Methods

Expression levels and CpG promoter methylation status of all MMR genes were evaluated in DNA from tumor and adjacent mucosal samples of 53 incident CRC patients.

Results

We have found significantly increased transcription levels in EXO1 gene in tumor tissues (P = 0.05) and significant over-expression of MSH3 gene in colon tumors when compared to adjacent mucosal tissues (P = 0.02). Interestingly, almost all MMR genes were differently expressed when localization of tumors was compared. In particular, colon tumors showed an up-regulation of EXO1, MSH2, MSH3, MSH6, and PMS2 genes in comparison to rectal tumors (P = 0.02). Expression levels of all MMR genes positively correlated between each other. The promoter methylation of MLH1 gene was observed in 9% of CRC tissues only.

Conclusions

In our study, we have observed different pattern of MMR genes expression according to tumor localization. However, a lack of association between methylation in MMR genes and their corresponding expressions was noticed in this study, the relationship between these two aspects is worthy to be analyzed in larger population studies and in pre-malignant stages.

【 授权许可】

   
2014 Vymetalkova et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
• [2]Naccarati A, Pardini B, Landi S, Landi D, Slyskova J, Novotny J, Levy M, Polakova V, Lipska L, Vodicka P: Polymorphisms in miRNA-binding sites of nucleotide excision repair genes and colorectal cancer risk. Carcinogenesis 2012, 33(7):1346-1351.
• [3]Center M, Jemal A, Ward E: International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev 2009, 18(6):1688-1694.
• [4]Center M, Jemal A, Smith R, Ward E: Worldwide variations in colorectal cancer. CA Cancer J Clin 2009, 59(6):366-378.
• [5]Theodoratou E, Montazeri Z, Hawken S, Allum G, Gong J, Tait V, Kirac I, Tazari M, Farrington S, Demarsh A, et al.: Systematic meta-analyses and field synopsis of genetic association studies in colorectal cancer. J Natl Cancer Inst 2012, 104(19):1433-1457.
• [6]Burgart L: Testing for defective DNA mismatch repair in colorectal carcinoma: a practical guide. Arch Pathol Lab Med 2005, 129(11):1385-1389.
• [7]Arends M: Pathways of colorectal carcinogenesis. Appl Immunohistochem Mol Morphol 2013, 21(2):97-102.
• [8]Curtin K, Slattery M, Samowitz W: CpG island methylation in colorectal cancer: past, present and future. Pathol Res Int 2011, 2011:8. Article ID 902674
• [9]Venkatachalam R, Ligtenberg M, Hoogerbrugge N, de Bruijn D, Kuiper R, Geurts van Kessel A: The epigenetics of (hereditary) colorectal cancer. Cancer Genet Cytogenet 2010, 203(1):1-6.
• [10]English D, Young J, Simpson J, Jenkins M, Southey M, Walsh M, Buchanan D, Barker M, Haydon A, Royce S, et al.: Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype. Cancer Epidemiol Biomarkers Prev 2008, 17(7):1774-1780.
• [11]Nosho K, Irahara N, Shima K, Kure S, Kirkner G, Schernhammer E, Hazra A, Hunter D, Quackenbush J, Spiegelman D, et al.: Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One 2008, 3(11):1-12.
• [12]Slattery M, Curtin K, Wolff R, Boucher K, Sweeney C, Edwards S, Caan B, Samowitz W: A comparison of colon and rectal somatic DNA alterations. Dis Colon Rectum 2009, 52(7):1304-1311.
• [13]Shen L, Toyota M, Kondo Y, Lin E, Zhang L, Guo Y, Hernandez N, Chen X, Ahmed S, Konishi K, et al.: Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci U S A 2007, 104(47):18654-18659.
• [14]Sinicrope FA, Foster NR, Thibodeau SN, Marsoni S, Monges G, Labianca R, Kim GP, Yothers G, Allegra C, Moore MJ, et al.: DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. J Natl Cancer Inst 2011, 103(11):863-875.
• [15]van Roon E, van Puijenbroek M, Middeldorp A, van Eijk R, de Meijer E, Erasmus D, Wouters K, van Engeland M, Oosting J, Hes F, et al.: Early onset MSI-H colon cancer with MLH1 promoter methylation, is there a genetic predisposition? BMC Cancer 2010, 10:1-10. BioMed Central Full Text
• [16]Poynter J, Haile R, Siegmund K, Campbell P, Figueiredo J, Limburg P, Young J, Le Marchand L, Potter J, Cotterchio M, et al.: Associations between smoking, alcohol consumption, and colorectal cancer, overall and by tumor microsatellite instability status. Cancer Epidemiol Biomarkers Prev 2009, 18(10):2745-2750.
• [17]Worthley DL, Whitehall VL, Spring KJ, Leggett BA: Colorectal carcinogenesis: road maps to cancer. World J Gastroenterol 2007, 13(28):3784-3791.
• [18]Goel A, Xicola R, Nguyen T, Doyle B, Sohn V, Bandipalliam P, Rozek L, Reyes J, Cordero C, Balaguer F, et al.: Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency. Gastroenterology 2010, 138(5):1854-1862.
• [19]Berg KD, Glaser CL, Thompson RE, Hamilton SR, Griffin CA, Eshleman JR: Detection of microsatellite instability by fluorescence multiplex polymerase chain reaction. J Mol Diagn 2000, 2(1):20-28.
• [20]Spurgeon SL, Jones RC, Ramakrishnan R: High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One 2008, 3(2):e1662.
• [21]Li LC, Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18(11):1427-1431.
• [22]Petko Z, Ghiassi M, Shuber A, Gorham J, Smalley W, Washington MK, Schultenover S, Gautam S, Markowitz SD, Grady WM: Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clin Cancer Res 2005, 11(3):1203-1209.
• [23]Slyskova J, Korenkova V, Collins AR, Prochazka P, Vodickova L, Svec J, Lipska L, Levy M, Schneiderova M, Liska V, et al.: Functional, genetic, and epigenetic aspects of base and nucleotide excision repair in colorectal carcinomas. Clin Cancer Res 2012, 18(21):5878-5887.
• [24]Oster B, Thorsen K, Lamy P, Wojdacz TK, Hansen LL, Birkenkamp-Demtroder K, Sorensen KD, Laurberg S, Orntoft TF, Andersen CL: Identification and validation of highly frequent CpG island hypermethylation in colorectal adenomas and carcinomas. Int J Cancer 2011, 129(12):2855-2866.
• [25]Tsai HC, Baylin SB: Cancer epigenetics: linking basic biology to clinical medicine. Cell Res 2011, 21(3):502-517.
• [26]Vasovcak P, Pavlikova K, Sedlacek Z, Skapa P, Kouda M, Hoch J, Krepelova A: Molecular genetic analysis of 103 sporadic colorectal tumours in Czech patients. PLoS One 2011, 6(8):e24114.
• [27]Samowitz WS, Curtin K, Wolff RK, Tripp SR, Caan BJ, Slattery ML: Microsatellite instability and survival in rectal cancer. Cancer Causes Control 2009, 20(9):1763-1768.
• [28]Takahashi K, Sugi Y, Nakano K, Tsuda M, Kurihara K, Hosono A, Kaminogawa S: Epigenetic control of the host gene by commensal bacteria in large intestinal epithelial cells. J Biol Chem 2011, 286(41):35755-35762.
• [29]Jones PA: Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012, 13(7):484-492.
• [30]Ioana M, Angelescu C, Burada F, Mixich F, Riza A, Dumitrescu T, Alexandru D, Ciurea T, Cruce M, Saftoiu A: MMR gene expression pattern in sporadic colorectal cancer. J Gastrointestin Liver Dis 2010, 19(2):155-159.
• [31]Caradec J, Sirab N, Revaud D, Keumeugni C, Loric S: Is GAPDH a relevant housekeeping gene for normalisation in colorectal cancer experiments? Br J Cancer 2010, 103(9):1475-1476.
• [32]Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, Schernhammer ES, Hunter DJ, Giovannucci EL, Fuchs CS, et al.: Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer 2010, 9:125. BioMed Central Full Text
• [33]Ide T, Kitajima Y, Ohtaka K, Mitsuno M, Nakafusa Y, Miyazaki K: Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. Oncol Rep 2008, 19(6):1571-1576.
• [34]Tentori L, Muzi A, Dorio AS, Dolci S, Campolo F, Vernole P, Lacal PM, Praz F, Graziani G: MSH3 expression does not influence the sensitivity of colon cancer HCT116 cell line to oxaliplatin and poly(ADP-ribose) polymerase (PARP) inhibitor as monotherapy or in combination. Cancer Chemother Pharmacol 2013, 72(1):117-125.
• [35]Kapiteijn E, Liefers GJ, Los LC, Kranenbarg EK, Hermans J, Tollenaar RA, Moriya Y, van de Velde CJ, van Krieken JH: Mechanisms of oncogenesis in colon versus rectal cancer. J Pathol 2001, 195(2):171-178.
• [36]Jiricny J: MutLalpha: at the cutting edge of mismatch repair. Cell 2006, 126(2):239-241.
• [37]Vageli DP, Giannopoulos S, Doukas SG, Kalaitzis C, Giannakopoulos S, Giatromanolaki A, Koukoulis GK, Touloupidis S: Mismatch repair hMSH2, hMLH1, hMSH6 and hPMS2 mRNA expression profiles in precancerous and cancerous urothelium. Oncol Lett 2013, 5(1):283-294.
• [38]Peltomaki P: Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol 2003, 21(6):1174-1179.
• [39]Martin-Lopez JV, Fishel R: The mechanism of mismatch repair and the functional analysis of mismatch repair defects in Lynch syndrome. Fam Cancer 2013, 12(2):159-168.